Dapagliflozin Propanediol

The dosage of Dapagliflozin Propanediol is highly standardized but must be individualized based on the patient's specific medical condition and renal (kidney) function.

• Type 2 Diabetes Mellitus: The recommended starting dose is 5 mg taken orally once daily in the morning. If the patient requires additional glycemic control and tolerates the 5 mg dose well, the healthcare provider may increase the dose to 10 mg once daily.
• Heart Failure (HFrEF/HFpEF): The recommended dose is 10 mg taken orally once daily. Unlike diabetes management, the dose for heart failure usually starts and remains at 10 mg to achieve the full cardiovascular benefits observed in clinical trials.
• Chronic Kidney Disease (CKD): The recommended dose is 10 mg taken orally once daily. Therapy is typically initiated in patients with an eGFR (estimated glomerular filtration rate) of at least 25 mL/min/1.73 m².

As of 2024-2026 guidelines, Dapagliflozin Propanediol is primarily approved for use in adults (18 years and older). While some clinical trials have explored the use of SGLT2 inhibitors in pediatric populations with type 2 diabetes (ages 10-17), safety and efficacy have not been as extensively established as in adults. Use in children must be strictly supervised by a pediatric endocrinologist and is generally considered off-label or restricted to specific regulatory approvals in certain regions.

Renal Impairment

Renal function must be assessed via eGFR before starting Dapagliflozin Propanediol and periodically thereafter.

• eGFR 45 to <95: No dosage adjustment is typically required.
• eGFR 25 to <45: Initiation is appropriate for CKD and heart failure at 10 mg. For glucose control in T2DM, the efficacy is reduced in this range.
• eGFR <25: Initiation is generally not recommended due to limited data, although patients already on the medication for CKD may sometimes continue therapy until they reach dialysis, depending on clinical judgment.
• Dialysis: Dapagliflozin Propanediol is contraindicated (should not be used) in patients on dialysis.

Hepatic Impairment

• Mild to Moderate: No dosage adjustment is necessary for patients with mild or moderate liver impairment.
• Severe (Child-Pugh Class C): Data are limited. A lower starting dose of 5 mg may be considered, and the patient should be monitored closely for safety.

Elderly Patients

No specific dosage adjustment is required based on age alone. However, elderly patients (65 and older) are more likely to have decreased renal function and a higher risk of volume depletion (dehydration). Healthcare providers often monitor blood pressure and kidney labs more frequently in this population.

• Timing: Take the medication once daily, preferably in the morning. This helps avoid 'nocturia' (waking up at night to urinate) because the drug increases urine production.
• With or Without Food: The tablets may be taken with or without food. Swallow the tablet whole with a glass of water.
• Crushing/Splitting: It is generally recommended to swallow the tablet whole. If you have difficulty swallowing, consult your pharmacist before crushing or splitting the tablet, as this may affect the drug's absorption rate.
• Storage: Store at room temperature (20°C to 25°C or 68°F to 77°F). Keep the bottle tightly closed and away from excessive moisture or direct sunlight.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not take two doses at the same time to make up for a missed one, as this increases the risk of side effects like dehydration or low blood sugar.

In the event of an overdose, contact your local poison control center or seek emergency medical attention immediately. Symptoms of a significant overdose may include severe dehydration, dizziness, rapid heartbeat, or signs of ketoacidosis (nausea, vomiting, abdominal pain). Treatment is supportive, focusing on rehydration and monitoring electrolyte levels.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this could lead to a rapid increase in blood sugar or worsening of heart failure symptoms.

Because Dapagliflozin Propanediol works by increasing glucose in the urine, it creates an environment where bacteria and fungi can thrive. The most common side effects include:

• Genital Mycotic Infections (Yeast Infections): This is the most frequently reported side effect. In females, symptoms include vaginal itching, odor, or discharge. In males, it may present as redness, itching, or swelling of the penis (balanitis). These are generally mild and can be treated with over-the-counter or prescription antifungal creams.
• Increased Urination (Polyuria): Patients often notice they need to urinate more frequently or in larger volumes. This is due to the osmotic effect of glucose pulling water into the urine.
• Urinary Tract Infections (UTIs): Increased glucose in the urinary tract can lead to common UTIs. Symptoms include a burning sensation during urination, cloudy urine, or pelvic pain.

• Back Pain: Some patients report mild to moderate musculoskeletal pain.
• Nausea: This is usually transient and occurs during the first few weeks of therapy.
• Dyslipidemia: A slight increase in LDL cholesterol (the 'bad' cholesterol) has been observed in some clinical trials.
• Dizziness/Lightheadedness: Often a result of the mild diuretic effect causing a slight drop in blood pressure.

• Increased Hematocrit: The drug can cause a slight increase in red blood cell concentration due to fluid loss.
• Thirst (Polydipsia): A natural response to the increased fluid loss through urination.
• Constipation: Secondary to mild dehydration.

While rare, some side effects are life-threatening and require emergency care.

> Warning: Stop taking Dapagliflozin Propanediol and call your doctor immediately if you experience any of these:

1. 1Ketoacidosis (Diabetic Ketoacidosis/DKA): This is a serious condition where the body produces high levels of blood acids (ketones). Uniquely, SGLT2 inhibitors can cause 'euglycemic DKA,' where blood sugar levels are not significantly elevated, making it harder to diagnose. Symptoms include nausea, vomiting, stomach pain, confusion, and difficulty breathing.
2. 2Fournier’s Gangrene (Necrotizing Fasciitis of the Perineum): This is a rare but extremely serious bacterial infection of the tissue under the skin in the genital area. Symptoms include pain, tenderness, redness, or swelling in the genital or anal area, along with fever and malaise.
3. 3Urosepsis and Pyelonephritis: Severe urinary tract infections that spread to the kidneys or the bloodstream. Symptoms include high fever, chills, and severe side or back pain.
4. 4Volume Depletion (Dehydration): Excessive loss of body water and salt can lead to kidney injury. Symptoms include extreme thirst, dry mouth, fainting, or severe dizziness when standing up.
5. 5Hypoglycemia (Low Blood Sugar): While Dapagliflozin Propanediol itself rarely causes low blood sugar, the risk increases significantly if it is taken with insulin or a sulfonylurea. Symptoms include shakiness, sweating, fast heartbeat, and blurred vision.

• Bone Fractures: Some studies of the SGLT2 class suggested a potential increase in fracture risk, although data for Dapagliflozin specifically have been largely reassuring. Patients with existing osteoporosis should be monitored.
• Renal Function Changes: Initially, there may be a small 'dip' in eGFR (kidney filtration rate). However, long-term data show that the drug actually protects the kidneys and slows the decline of renal function over years of use.
• Vitamin B12 Deficiency: While more common with Metformin, patients on combination therapies should have their B12 levels checked periodically.

No FDA black box warnings currently exist for Dapagliflozin Propanediol. Unlike some other drugs in the SGLT2 class (like Canagliflozin), Dapagliflozin does not carry a black box warning for lower limb amputation, though healthcare providers still advise routine foot care for all diabetic patients.

Report any unusual symptoms to your healthcare provider. Early detection of side effects like yeast infections or dehydration can prevent them from becoming serious medical issues.

Dapagliflozin Propanediol is a potent medication that affects fluid balance and metabolic processes. It is essential for patients to remain hydrated and to monitor for signs of metabolic distress. This medication should only be used under the strict supervision of a healthcare professional who can perform regular blood and urine tests.

As of 2026, there are no FDA black box warnings for Dapagliflozin Propanediol. It has a well-established safety profile when used according to guidelines.

• Ketoacidosis Risk: Patients with type 1 diabetes or those undergoing major surgery are at a higher risk. It is often recommended to stop the medication at least 3 days before scheduled surgery to prevent 'euglycemic ketoacidosis.'
• Volume Depletion and Hypotension: Because the drug acts as a mild diuretic, it can cause a drop in blood pressure. This is especially dangerous for patients already taking 'water pills' (diuretics) or those with very low blood pressure. If you feel faint or dizzy when standing, contact your doctor.
• Acute Kidney Injury (AKI): While the drug is kidney-protective in the long run, the initial fluid loss can cause temporary kidney stress. Patients should avoid other nephrotoxic (kidney-damaging) drugs like NSAIDs (e.g., ibuprofen, naproxen) while starting this medication.
• Genital Infections: Patients with a history of chronic yeast infections should discuss this with their doctor, as the risk of recurrence is high.
• Lower Limb Amputation: Although not a boxed warning, patients with peripheral vascular disease or a history of foot ulcers should monitor their feet daily for sores, infections, or pain.

Your healthcare provider will likely require the following tests:

• eGFR/Creatinine: To monitor kidney function (at least twice a year).
• HbA1c: To monitor blood sugar control (every 3-6 months).
• Blood Pressure: To ensure the diuretic effect is not causing hypotension.
• Potassium and Electrolytes: Especially if you are taking ACE inhibitors or ARBs for your heart.
• Foot Exams: Regular checks for skin integrity, especially in patients with neuropathy.

Dapagliflozin Propanediol generally does not affect the ability to drive. However, if you experience dizziness due to low blood pressure or shakiness from low blood sugar (if used with insulin), do not operate heavy machinery until you feel stable.

Alcohol should be consumed with extreme caution. Alcohol can increase the risk of ketoacidosis and dehydration. It can also mask the symptoms of low blood sugar. It is generally advised to limit alcohol intake to moderate levels and always consume it with food.

Do not stop taking Dapagliflozin Propanediol suddenly unless instructed by your doctor (e.g., in the case of a serious side effect). Stopping the drug may cause a rapid rise in blood glucose levels or a sudden worsening of heart failure symptoms. There is no 'withdrawal syndrome' per se, but the underlying conditions (diabetes/HF) may rebound quickly.

> Important: Discuss all your medical conditions, including any history of pancreas problems, alcohol abuse, or frequent urinary tract infections, with your healthcare provider before starting Dapagliflozin Propanediol.

There are few absolute contraindications for drug combinations with Dapagliflozin Propanediol, but the following require extreme caution:

• Dialysis: The drug is not effective and should not be used in patients undergoing dialysis.
• Hypersensitivity: Do not use with any medication if a previous severe allergic reaction to SGLT2 inhibitors has occurred.

• Insulin and Insulin Secretagogues (Sulfonylureas): When combined with Dapagliflozin Propanediol, the risk of severe hypoglycemia (dangerously low blood sugar) increases. Your doctor may need to lower your insulin or sulfonylurea dose (e.g., glipizide, glyburide) when starting this drug.
• Diuretics (Water Pills): Medications like furosemide (Lasix) or hydrochlorothiazide can increase the risk of dehydration and low blood pressure when taken with Dapagliflozin. This can lead to acute kidney injury.
• Lithium: SGLT2 inhibitors can increase the renal excretion of lithium, potentially lowering lithium levels in the blood and reducing its effectiveness for mood stabilization. Frequent monitoring of lithium levels is required.

• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs): Ibuprofen, naproxen, and high-dose aspirin can stress the kidneys. Combining these with Dapagliflozin may increase the risk of renal impairment.
• ACE Inhibitors and ARBs: While often prescribed together for heart or kidney protection, the combination can initially cause a dip in kidney function and changes in potassium levels.

• High-Fat Meals: Can delay the absorption of the drug but do not change the overall amount of drug absorbed. No specific food restrictions are required.
• Caffeine: High intake of caffeine can worsen the diuretic effect, leading to increased frequency of urination and potential dehydration.

• St. John's Wort: May potentially induce the enzymes that metabolize Dapagliflozin, although the clinical impact is likely minor.
• Glucosamine: Some studies suggest glucosamine might interfere with blood sugar control, potentially working against the effects of Dapagliflozin.
• Diuretic Herbs: Herbs like dandelion or juniper may increase the risk of dehydration.

• Urine Glucose Test: Because Dapagliflozin Propanediol works by putting glucose into the urine, a urine glucose test will always be positive. This test should not be used to monitor diabetes control while on this medication.
• 1,5-AG Assay: This specific blood test for glucose control is unreliable in patients taking SGLT2 inhibitors. Use HbA1c instead.

For each major interaction, the mechanism usually involves either a pharmacodynamic synergy (two drugs doing the same thing, like lowering blood pressure) or a change in renal clearance. The management strategy typically involves more frequent monitoring of lab values or adjusting the dose of the other medication.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.

There are certain conditions where Dapagliflozin Propanediol must NEVER be used because the risks far outweigh any potential benefits:

1. 1Serious Hypersensitivity: Patients who have had a history of anaphylaxis (severe allergic reaction), angioedema (swelling under the skin), or severe skin reactions to Dapagliflozin or any of its excipients.
2. 2Dialysis: The mechanism of the drug depends on functioning nephrons. In patients on dialysis, the drug is ineffective and may cause unnecessary side effects.
3. 3Type 1 Diabetes (for certain indications): While sometimes used off-label, it is not FDA-approved for Type 1 Diabetes due to a significantly high risk of diabetic ketoacidosis (DKA).

These are conditions where the drug may be used, but only with extreme caution and careful risk-benefit analysis by a specialist:

• Severe Hepatic Impairment: Due to limited data in Child-Pugh Class C patients.
• Active Bladder Cancer: There were early concerns about a slight increase in bladder cancer cases in clinical trials, though later data were less conclusive. It is generally avoided in patients with active bladder cancer.
• History of Fournier’s Gangrene: If a patient has previously suffered from this necrotizing infection, SGLT2 inhibitors are usually avoided.
• Low eGFR (<25): Initiation is generally contraindicated for glycemic control, though it may be used for CKD/HF under specific guidelines.

Patients who have had an allergic reaction to other SGLT2 inhibitors, such as Canagliflozin (Invokana) or Empagliflozin (Jardiance), may experience a cross-reaction with Dapagliflozin Propanediol. Always inform your doctor if you have had a reaction to any 'gliflozin' medication.

> Important: Your healthcare provider will evaluate your complete medical history, including your kidney function and any history of cancer or severe infections, before prescribing Dapagliflozin Propanediol.

Dapagliflozin Propanediol is not recommended during the second and third trimesters of pregnancy. Based on animal data, the drug may affect renal development and maturation in the fetus.

• First Trimester: Data are limited. It is generally advised to switch to insulin, which is the gold standard for blood sugar control during pregnancy.
• FDA Category: While the FDA has moved away from letter categories (A, B, C, D, X), the current narrative warnings emphasize the risk of fetal kidney damage during the later stages of pregnancy.

It is not known if Dapagliflozin Propanediol passes into human breast milk. However, because animal studies show the drug is excreted in milk and can affect the developing kidneys of the offspring, breastfeeding is generally not recommended while taking this medication. Mothers should discuss alternative treatments or formula feeding with their healthcare provider.

Dapagliflozin Propanediol is not established as safe or effective in children under the age of 18 for most indications. While some regions have approved it for T2DM in children over 10, it is not used for heart failure or CKD in pediatric populations. Growth and development are not known to be affected, but the risk of ketoacidosis may be higher in younger patients.

Patients aged 65 and older are at a higher risk of:

• Volume Depletion: Older adults have a decreased thirst mechanism and are more prone to dehydration.
• Renal Impairment: Kidney function naturally declines with age, making the drug less effective for glucose control and increasing the risk of side effects.
• Falls: Dizziness from low blood pressure (orthostatic hypotension) can increase the risk of falls and fractures.

Despite these risks, the cardiovascular and renal benefits in the elderly are significant, and the drug is frequently used with close monitoring.

• eGFR 25-60: The drug is highly effective for heart failure and kidney protection but less effective for lowering blood sugar.
• eGFR <25: Not recommended for initiation.
• End-Stage Renal Disease (ESRD): Contraindicated.

No adjustment is needed for mild to moderate liver disease. In severe liver disease, the exposure to the drug increases, and a 5 mg dose is preferred as a starting point.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are planning to become pregnant or are over the age of 75.

Dapagliflozin Propanediol is a potent and competitive inhibitor of the Sodium-Glucose Cotransporter 2 (SGLT2). SGLT2 is expressed almost exclusively in the S1 segment of the proximal convoluted tubule in the kidney. By binding to this transporter, Dapagliflozin prevents the reabsorption of filtered glucose back into the tubular capillaries. This leads to the excretion of approximately 70 grams of glucose per day in the urine. Additionally, because sodium reabsorption is coupled with glucose reabsorption in this transporter, the drug also causes natriuresis (sodium loss). This reduction in sodium reabsorption helps restore the tubuloglomerular feedback mechanism, leading to afferent arteriolar vasoconstriction and a reduction in high pressure within the kidney (hyperfiltration), which is the primary mechanism for its kidney-protective effects.

• Glucose Excretion: The amount of glucose removed via the urine is dependent on the blood glucose concentration and the eGFR. In patients with higher blood sugar, more glucose is excreted.
• Blood Pressure: A modest reduction in systolic blood pressure (typically 3-5 mmHg) is observed due to the osmotic diuresis and natriuresis.
• Weight Loss: The loss of calories through glucosuria leads to an average weight loss of 2-3 kg over 6 months.

| Parameter | Value |

|---|---|

| Bioavailability | 78% |

| Protein Binding | ~91% |

| Half-life | 12.9 hours |

| Tmax | 1-2 hours (fasted) |

| Metabolism | Primarily UGT1A9 |

| Excretion | Renal 75%, Fecal 21% |

• Molecular Formula: C21H25ClO6 (Dapagliflozin) • C3H8O2 (Propanediol) • H2O (Water)
• Molecular Weight: 502.98 g/mol (monohydrate form)
• Solubility: Highly soluble in water and ethanol.
• Structure: A C-glucoside with a chloro-substituted phenyl ring and an ethoxyphenyl group, which provides high selectivity for SGLT2 over SGLT1 (the transporter in the gut).

Dapagliflozin belongs to the SGLT2 inhibitor class. Related medications include Empagliflozin (Jardiance), Canagliflozin (Invokana), and Ertugliflozin (Steglatro). It is considered a 'non-insulin-dependent' antihyperglycemic agent.